ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Genetic Analysis of Oculocerebrorenal Syndrome of Lowe

This study is ongoing, but not recruiting participants.

Sponsored by: National Human Genome Research Institute (NHGRI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00359515
  Purpose

This study will investigate the genetic basis of oculocerebrorenal syndrome of Lowe (OCRL)-a rare X-linked disorder (carried by females and passed to males). Patients with OCRL have abnormal development of the eye lens, developmental delay, muscle weakness and kidney dysfunction.

The study will examine DNA and cell samples obtained and archived from patients with OCRL enrolled in a previous protocol (HG008A) between 1996 and 1999. It will identify mutations in the OCRL1 gene responsible for OCRL in affected males and try to correlate them with specific biochemical or cellular activities (e.g., enzyme activity, protein stability, cellular localization and trafficking). When test results are available, the information will be communicated to the patients, their parents (if the patient is a minor) and their physicians, and families will receive genetic counseling.


Condition
Lowe Syndrome

Genetics Home Reference related topics:   L1 syndrome    Lowe syndrome    Opitz G/BBB syndrome   

U.S. FDA Resources

Study Type:   Observational
Official Title:   Mutation Detection for Lowe Syndrome

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:   120
Study Start Date:   February 2001

Detailed Description:

Oculocerebrorenal syndrome of Lowe (OCRL) is a rare X-linked disorder characterized by congenital cataracts, mental retardation, and renal tubular dysfunction. Patients with known or suspected OCRL were enrolled under previous protocol 96-HG-0008 that expired in 1998 and was not renewed. We are continuing studies of DNA and cell samples obtained and archived under our previous protocol to identify mutations in the OCRL1 gene responsible for Lowe syndrome and related disorders in affected males and attempt to correlate these mutations to particular biochemical or cellular phenotypes (enzyme activity, protein stability, cellular localization and trafficking). Information about genotypes will not be communicated back to the patients, their parents (if patient is a minor) or their physicians as part of this study.

We are also continuing our investigations of heterogeneity in OCRL by studying collected cell cultures from our collaborator Dr. Steven Scheinman at Suny New York Medical University, Syracuse, from a group of patients with mutations in OCRL1 who have Dent disease, characterized by renal tubular dysfunction. These data, and the variability in the renal and CNS abnormalities that occur in OCRL are evidence for the existence of modifiers. We propose to identify genes that are differentially expressed in cells from OCRL patients, patients with Dent disease and OCRL1 mutations by gene expression analysis of RNA from patient samples.

As part of our study on phenotypic and genetic heterogeneity in OCRL, mutation analysis resulted in the identification of mutations mostly in the second two-thirds of OCRL1. However, the OCRL1 mutations in the Dent disease patients have been found in the first third of OCRL1. We plan to send samples from Lowe syndrome patients without identified OCRL1 mutations to a Dr. Steven Scheinman who will look for such OCRL1 mutations. He will be sent only coded samples and will look for such OCRL1 mutations. He will be sent only coded samples and will not have access to patient identifiers. This information will be used for research purposes only.

  Eligibility
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Criteria
  • INCLUSION CRITERIA:

Male gender, history of congenital cataracts, proximal renal tubular dysfunction, and developmental delay.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00359515

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike    
      Bethesda, Maryland, United States, 20892

Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   010095, 01-HG-0095
First Received:   August 1, 2006
Last Updated:   July 18, 2008
ClinicalTrials.gov Identifier:   NCT00359515
Health Authority:   United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Archived Samples  
Mutation Screening  
Genotype-Phenotype Correlation  
Pediatric Developmental Disorder  
Cataracts  
Mutation Detection
Lowe Syndrome
Mutation Screening
Genotype

Study placed in the following topic categories:
Developmental Disabilities
Metabolic Diseases
Oculocerebrorenal Syndrome
Central Nervous System Diseases
Lowe oculocerebrorenal syndrome
Brain Diseases
Metabolism, Inborn Errors
Urologic Diseases
Genetic Diseases, Inborn
Cataract
Abnormalities, Multiple
Genetic Diseases, X-Linked
Brain Diseases, Metabolic, Inborn
Kidney Diseases
Metabolic disorder
Congenital Abnormalities
Oculocerebrorenal syndrome
Brain Diseases, Metabolic

Additional relevant MeSH terms:
Pathologic Processes
Disease
Amino Acid Transport Disorders, Inborn
Syndrome
Nervous System Diseases
Renal Tubular Transport, Inborn Errors

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers